Trial Search Results
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
The purpose of this study is to find if Lurbinectedin, the study drug can help delay worsening of epithelian ovarian, fallopian tube or peritoneal cancer when compared to PLD or topotecan among patients who are resistant to platinum.
Stanford is currently not accepting patients for this trial.
- Drug: Lurbinectedin (PM01183)
- Drug: Pegylated liposomal doxorubicin (PLD)
- Drug: Topotecan
- Age >/= 18 years
- Confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary
- Platinum-resistant disease (PFI: 1-6 months after last platinum-containing
- Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
- No more than three prior systemic chemotherapy regimens
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) (ECOG PS) ≤ 2
- Adequate hematological, renal, metabolic and hepatic function
- Concomitant diseases/conditions: cardiac disease, immunodeficiency, chronic active
hepatitis or cirrhosis, uncontrolled infection, bowel obstruction, any other major
- Prior treatment with PM01183, trabectedin, or with both PLD and topotecan.
- Requirement of permanent or frequent (i.e., once per week) external drainages within
two weeks prior to randomization
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study